Welcome to our dedicated page for AMERICAN VANGUARD SEC filings (Ticker: AVD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
American Vanguard Corporation's SEC filings document the formal disclosures of a NYSE-listed specialty agriculture products company and its AMVAC Chemical Corporation operating subsidiary. Recent Form 8-K reports cover operating results, earnings-call materials, Regulation FD disclosures and material credit arrangements, including term-loan and revolving-credit amendments tied to the company's capital structure and working-capital needs.
Proxy and annual-meeting filings address board elections, director composition, auditor ratification, executive compensation and shareholder voting matters. The filings also identify the company's common stock, par value, exchange listing and governance actions related to board size and committee-level oversight.
AMERICAN VANGUARD CORP (AVD) director-affiliated entities reported a significant common stock sale. On 2026-08-18, investment funds and separately managed accounts advised by Cruiser Capital Advisors, LLC, an affiliate of director Keith M. Rosenbloom, sold 556,580 shares of common stock at $2.20 per share. After this transaction, entities associated with Cruiser Capital reported 15,201 shares held indirectly, while Rosenbloom reported 66,283 shares held directly. Rosenbloom may be deemed to share voting and dispositive power over the Cruiser-held shares but disclaims beneficial ownership except to the extent of his pecuniary interest. The filing states the reported sale relates to securities held only by the Cruiser funds and accounts and was undertaken for reasons unrelated to American Vanguard’s business, operations or prospects.
AMERICAN VANGUARD CORP (AVD) director Steven D. Macicek reported a purchase of company stock. On 2026-08-17, he bought 19,000 shares of AVD common stock in an open-market or private transaction at $2.09 per share, bringing his directly held stake to 99,711 shares.
American Vanguard Corporation reported weaker second-quarter 2026 results but stronger first-half profitability and reaffirmed its full-year outlook. Net sales in the quarter were $116.8 million, down 10% year over year, driven mainly by an 18% decline in international revenue, while U.S. sales fell 3%. The company posted a Q2 net loss of $9.9 million versus a $0.8 million loss a year earlier, pressured by higher interest expense and freight costs.
For the first half, net sales were $240.3 million, down 2%, but gross margin improved from 29% to 30%, and Adjusted EBITDA rose to $16.9 million from $14.0 million, reflecting cost reductions and transformation efforts. Operating cash flow was negative $60.5 million, and net debt was about $224.7 million at June 30, 2026. Management highlights ongoing benefits from the L.A. plant rationalization, expected to save at least $4 million annually, and continued R&D investment. The company reaffirmed 2026 guidance for Adjusted EBITDA of $44–48 million on sales of $530–550 million and outlined a goal of reaching an annualized revenue run rate above $600 million by the back half of 2028 with double-digit EBITDA margins.
American Vanguard reported weaker results for the quarter ended June 30, 2026. Net sales fell 10% to $116.8 million, driven by lower U.S. crop and international sales, partly offset by 11% growth in U.S. Specialty. Gross profit declined 14% to $34.7 million and gross margin slipped to 30% from 31%.
Operating performance deteriorated from $4.4 million income to a small $0.3 million loss, and higher leverage pushed net interest expense to $9.1 million from $4.5 million. The quarter’s net loss widened to $9.9 million, or $0.34 per share, versus a $0.8 million loss a year earlier. For the first six months, sales were down 2% to $240.3 million, but gross margin improved to 30% from 29%; net loss increased to $14.0 million.
Cash from operations was a use of $60.5 million for the first half, reflecting higher receivables, lower customer prepayments and program payouts, and transformation and plant reorganization costs linked to shifting production from the Los Angeles facility to the Axis site. This was funded by new term loans; total net indebtedness rose to $267.6 million, with a weighted-average interest rate of 12.0%, and cash increased to $43.9 million. The new First and Second Lien Term Loans include leverage and minimum cash covenants and restrict dividends and stock repurchases. Management states it is in covenant compliance and expects existing cash and operating cash flow to cover liquidity needs over the next twelve months.
BlackRock, Inc. reports its beneficial ownership of common stock of American Vanguard Corporation as of 06/30/2026. BlackRock and certain of its business units beneficially own 896,552 shares of American Vanguard common stock, representing 3.1% of the outstanding class.
BlackRock has sole voting power and sole dispositive power over all 896,552 shares, with no shared voting or dispositive power. The filing notes that various underlying clients or investors may have rights to dividends or sale proceeds, but no such person holds more than five percent of the total outstanding common shares of American Vanguard.
American Vanguard chief executive Douglas Kaye acquired 6,527 shares of common stock at $2.36 per share through the company's employee stock purchase plan. The shares were purchased via payroll deductions over a six-month period ending June 30, 2026, at 85% of fair market value. After this transaction, he holds 306,778 shares directly.
ROSENBLOOM KEITH M reported acquisition or exercise transactions in this Form 4 filing.
AMERICAN VANGUARD CORP director Keith M. Rosenbloom received a grant of 31,872 deferred stock units (DSUs) on Common Stock as part of the company’s 2026 non‑management director compensation program.
After this award, he directly holds 66,283 shares-equivalent, with each DSU settling into one common share when his board service ends, upon a change of control, or upon his death. The DSUs are nontransferable and carry no voting or dividend rights during his service.
American Vanguard Corp officer David T. Johnson received a grant of options to buy 20,000 shares of common stock. The options have an exercise price of $2.51 per share and were awarded as an incentive stock option grant.
The options vest in full on the third anniversary of the June 4, 2026 grant date and expire on the tenth anniversary. Following this award, Johnson holds options for 20,000 underlying common shares directly.
AMERICAN VANGUARD CORP director and CEO Douglas Kaye received a grant of 50,000 stock options. These options allow the purchase of 50,000 shares of Common Stock at an exercise price of $2.51 per share. The award is compensation-related, not an open-market trade.
The incentive stock options vest in full on the third anniversary of the June 4, 2026 grant date and expire on the tenth anniversary. After this grant, Kaye holds 50,000 options directly, giving potential future equity exposure if the options vest and are exercised.
American Vanguard Corporation reported the results of its 2026 annual stockholder meeting and approved special executive bonuses. Seven director nominees were elected, Deloitte Touche LLP was ratified as independent auditor for the year ending December 31, 2026, and stockholders backed annual advisory votes on pay and approved the company’s executive compensation program. The board also granted success bonuses tied to a full restructuring of the company’s borrowed debt: $150,000 to Douglas Kaye, $125,000 each to David Johnson and Timothy Donnelly, and $50,000 to Shirin Khosravi.